Blab Business
Corvention Secures FDA 510(k) Clearance for KardiaPSI Balloon Catheter, Plans Controlled Market Rollout
In a quiet Flagstaff office, a breakthrough that could change aortic‑valve treatment finally cleared the FDA’s most rigorous hurdle. Corvention, a medical‑device startup headquartered in Flagstaff, Arizona, announced in early 2026 that the U.S. Food and Drug Administration has granted 510(k) clearance for its KardiaPSI balloon catheter, a high‑pressure device engineered for aortic valve procedures.
"We are very excited and looking forward to a great 2026 for patients and families," said Corvention CEO and co‑founder Michael Franklin. The company said it will focus its initial efforts on building the commercial infrastructure and strategic support networks needed for a national launch. Franklin added, "As we enter commercialization, we are committed to a disciplined, high‑touch rollout and to being responsible stewards of the clinical spaces we serve, with a focus on supporting improved and durable patient outcomes."
The KardiaPSI catheter emerged from a partnership with POBA Medical, a Flagstaff‑based manufacturer that specializes in angioplasty‑style balloon and catheter development. According to Corvention, POBA and the company completed the entire production chain—from raw materials to finished medical product—within the Moonshot Flagstaff campus. The campus, operated by the non‑profit Moonshot Arizona, provides laboratory and office space, shared infrastructure, and access to a broader entrepreneurial network.
Corvention has been part of the Moonshot Flagstaff startup community since October 2024. The campus has supported the company’s early‑stage development through shared resources and networking opportunities. POBA Medical’s expertise in high‑volume balloon production proved critical to the KardiaPSI project, enabling the device to meet the stringent performance and safety standards required for FDA clearance.
FDA’s 510(k) clearance indicates that the KardiaPSI catheter is substantially equivalent to a legally marketed predicate device. While the clearance does not guarantee market success, it removes a major regulatory barrier and allows Corvention to begin clinical support and physician training programs. The company’s stated approach is to roll out the product in a disciplined, high‑touch manner, ensuring that clinicians receive comprehensive training and that patient outcomes are closely monitored.
Industry analysts note that the aortic valve market is growing, driven by an aging population and advances in transcatheter techniques. A high‑pressure balloon catheter such as KardiaPSI could offer a less invasive alternative to surgical valve replacement, potentially expanding treatment options for patients who are not candidates for traditional procedures.
Corvention’s CEO emphasized the importance of responsible stewardship of clinical spaces. "We want to support improved and durable patient outcomes," Franklin reiterated. The company has not yet disclosed specific timelines for a national launch, but the phased rollout plan suggests a gradual expansion that will begin with early adopters in select hospitals.
The collaboration with POBA Medical also highlights a trend in the medical‑device sector toward partnerships that combine design expertise with manufacturing capabilities. By completing the entire production process on the Moonshot Flagstaff campus, Corvention and POBA have demonstrated a streamlined supply chain that could reduce lead times and costs.
As Corvention prepares for its market introduction, it will need to secure additional resources for physician training, post‑market surveillance, and potential regulatory updates. The company has not announced any plans for additional funding rounds or partnerships beyond its current collaboration with POBA.
In summary, Corvention’s FDA clearance of the KardiaPSI balloon catheter represents a significant step toward making a new aortic valve treatment available to patients. The company’s focus on a controlled, high‑touch rollout and its partnership with POBA Medical position it to address both clinical and commercial challenges as it moves toward a national launch.
The next key milestones for Corvention will include the rollout of training programs for cardiologists, the establishment of a national distribution network, and the collection of real‑world data to support ongoing safety and effectiveness monitoring. The company’s progress will be closely watched by clinicians, investors, and regulators interested in the evolving landscape of minimally invasive cardiac devices.
"We are very excited and looking forward to a great 2026 for patients and families," said Corvention CEO and co‑founder Michael Franklin. The company said it will focus its initial efforts on building the commercial infrastructure and strategic support networks needed for a national launch. Franklin added, "As we enter commercialization, we are committed to a disciplined, high‑touch rollout and to being responsible stewards of the clinical spaces we serve, with a focus on supporting improved and durable patient outcomes."
The KardiaPSI catheter emerged from a partnership with POBA Medical, a Flagstaff‑based manufacturer that specializes in angioplasty‑style balloon and catheter development. According to Corvention, POBA and the company completed the entire production chain—from raw materials to finished medical product—within the Moonshot Flagstaff campus. The campus, operated by the non‑profit Moonshot Arizona, provides laboratory and office space, shared infrastructure, and access to a broader entrepreneurial network.
Corvention has been part of the Moonshot Flagstaff startup community since October 2024. The campus has supported the company’s early‑stage development through shared resources and networking opportunities. POBA Medical’s expertise in high‑volume balloon production proved critical to the KardiaPSI project, enabling the device to meet the stringent performance and safety standards required for FDA clearance.
FDA’s 510(k) clearance indicates that the KardiaPSI catheter is substantially equivalent to a legally marketed predicate device. While the clearance does not guarantee market success, it removes a major regulatory barrier and allows Corvention to begin clinical support and physician training programs. The company’s stated approach is to roll out the product in a disciplined, high‑touch manner, ensuring that clinicians receive comprehensive training and that patient outcomes are closely monitored.
Industry analysts note that the aortic valve market is growing, driven by an aging population and advances in transcatheter techniques. A high‑pressure balloon catheter such as KardiaPSI could offer a less invasive alternative to surgical valve replacement, potentially expanding treatment options for patients who are not candidates for traditional procedures.
Corvention’s CEO emphasized the importance of responsible stewardship of clinical spaces. "We want to support improved and durable patient outcomes," Franklin reiterated. The company has not yet disclosed specific timelines for a national launch, but the phased rollout plan suggests a gradual expansion that will begin with early adopters in select hospitals.
The collaboration with POBA Medical also highlights a trend in the medical‑device sector toward partnerships that combine design expertise with manufacturing capabilities. By completing the entire production process on the Moonshot Flagstaff campus, Corvention and POBA have demonstrated a streamlined supply chain that could reduce lead times and costs.
As Corvention prepares for its market introduction, it will need to secure additional resources for physician training, post‑market surveillance, and potential regulatory updates. The company has not announced any plans for additional funding rounds or partnerships beyond its current collaboration with POBA.
In summary, Corvention’s FDA clearance of the KardiaPSI balloon catheter represents a significant step toward making a new aortic valve treatment available to patients. The company’s focus on a controlled, high‑touch rollout and its partnership with POBA Medical position it to address both clinical and commercial challenges as it moves toward a national launch.
The next key milestones for Corvention will include the rollout of training programs for cardiologists, the establishment of a national distribution network, and the collection of real‑world data to support ongoing safety and effectiveness monitoring. The company’s progress will be closely watched by clinicians, investors, and regulators interested in the evolving landscape of minimally invasive cardiac devices.
